Researchers at Indiana University School of Medicine are celebrating Federal Drug Administration approval of teplizumab, a new immunotherapy drug that delays the onset of type 1 diabetes in at-risk individuals by an average of almost three years.
Researchers are investigating novel regenerative medicine approaches to better manage vascular health complications from type 2 diabetes that could someday support blood vessel repair in the eye among diabetic patients with early retinal vascular dysfunction.
For people with diabetes who are insulin dependent, glycemic control is a full-time job. But what if their medication could do the work for them—an insulin whose activity in the bloodstream responds to the blood glucose levels and adjusts accordingly?
A group of leading scientists is holding a mirror to the diabetes research community and calling for the improved support of its female constituents. Linda DiMeglio, MD, MPH, of Indiana University School of Medicine and Mark Atkinson, PhD, of the University of Florida, led a deep dive into the historical representation of women in the diabetes research community and that of women in influential positions among four major diabetes organizations.
Scientists have found that insulin has met an evolutionary cul-de-sac, limiting its ability to adapt to obesity and thereby rendering most people vulnerable to Type 2 diabetes. A recent study from scientists at Indiana University School of Medicine, the University of Michigan and Case Western Reserve University has determined that the sequence of insulin has become entrenched at the edge of impaired production, an intrinsic vulnerability unmasked by rare mutations in the insulin gene causing diabetes in childhood
Indiana University School of Medicine researchers are participating in the Rare and Atypical Diabetes Network (RADIANT), a nationwide study funded by the National Institutes of Health. The study seeks to discover new forms of diabetes, identify their causes, and understand how they differ from more common types of diabetes.
Indiana University School of Medicine is leading the first study of the national Diabetic Foot Consortium with the goal of preventing reopening of closed wounds by identifying a biomarker that would predict such recurrence during the process of standard wound care.
INDIANAPOLIS—Carmella Evans-Molina, MD, PhD, has been appointed director of the Center for Diabetes and Metabolic Diseases (CDMD) at Indiana University School of Medicine. Evans-Molina is the center’s second appointed director since it received designation from the National Institutes of Health in 2015. The center’s mission is to bring cutting-edge research tools to diabetes investigators at […]